贝伐珠单抗联合靶向药物治疗用于表皮生长因子受体突变型非小细胞肺癌患者的效果  

Effects of Bevacizumab combined with targeted drug therapy on patients with epidermal growth factor receptor-mutant non-small cell lung cancer

作　　者：董利[1] DONG Li(1^(st) Department of Oncology of Puyang People’s Hospital,Puyang 457000 Henan,China)

机构地区：[1]濮阳市人民医院肿瘤一科,河南濮阳457000

出　　处：《中国民康医学》2023年第20期68-70,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察贝伐珠单抗联合靶向药物治疗用于表皮生长因子受体(EGFR)突变型非小细胞肺癌(NSCLC)患者的效果。方法:回顾性分析2019年1月至2022年12月该院收治的69例EGFR突变型NSCLC患者的临床资料,按治疗方法不同将其分为观察组35例和对照组34例。对照组采用盐酸埃克替尼片靶向治疗,观察组在对照组基础上联合贝伐珠单抗注射液治疗,比较两组疗效,治疗前后血清肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、血管内皮生长因子(VEGF)、糖类抗原125(CA125)]水平、血清T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:观察组客观缓解率为74.29%,明显高于对照组的50.00%,差异有统计学意义(P<0.05);治疗后,两组血清CEA、CYFRA21-1、VEGF、CA125水平低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);治疗后,两组血清CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05);治疗期间,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合盐酸埃克替尼片靶向治疗用于EGFR突变型NSCLC患者可提高客观缓解率和血清CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平,降低血清CEA、CYFRA21-1、VEGF、CA125水平,效果优于单纯盐酸埃克替尼片靶向治疗。Objective:To observe effects of Bevacizumab combined with targeted drug therapy on patients with epidermal growth factor receptor(EGFR)-mutant non-small cell lung cancer(NSCLC).Methods:The clinical data of 69 patients with EGFR-mutant NSCLC admitted to the hospital from January 2019 to December 2022 were retrospectively analyzed.According to different treatment methods,they were divided into observation group(35 cases)and control group(34 cases).The control group was treated with targeted therapy of Icotinib hydrochloride tablets,while the observation group was treated with Bevacizumab injection on the basis of that of the control group.The efficacy,the levels of serum tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125)]levels and the serum T cell subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))before and after treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective response rate of treatment in the observation group was 74.29%,which was significantly higher than 50.00%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum CEA,CYFRA21-1,VEGF and CA125 in the two groups were lower than those before treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of serum CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Bevacizumab combined with Icotinib hydrochloride tablets targeted therapy for the EGFR-mutant NSCLC patients can improve the objective response rate of treatment

关 键 词：非小细胞肺癌 表皮生长因子受体突变型 贝伐珠单抗注射液 靶向治疗 T细胞亚群 肿瘤标志物 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]